ALKEM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.1
| Stock Code | ALKEM | Market Cap | 64,593 Cr. | Current Price | 5,397 ₹ | High / Low | 5,934 ₹ |
| Stock P/E | 29.2 | Book Value | 1,143 ₹ | Dividend Yield | 0.83 % | ROCE | 19.5 % |
| ROE | 19.9 % | Face Value | 2.00 ₹ | DMA 50 | 5,450 ₹ | DMA 200 | 5,444 ₹ |
| Chg in FII Hold | 0.18 % | Chg in DII Hold | -0.15 % | PAT Qtr | 654 Cr. | PAT Prev Qtr | 724 Cr. |
| RSI | 49.0 | MACD | -7.97 | Volume | 59,139 | Avg Vol 1Wk | 1,04,494 |
| Low price | 4,716 ₹ | High price | 5,934 ₹ | PEG Ratio | 2.10 | Debt to equity | 0.06 |
| 52w Index | 55.9 % | Qtr Profit Var | -3.35 % | EPS | 196 ₹ | Industry PE | 30.9 |
📊 Analysis: ALKEM demonstrates strong fundamentals with ROCE at 19.5% and ROE at 19.9%, reflecting efficient capital use and profitability. Debt-to-equity is very low at 0.06, ensuring financial stability. EPS of 196 ₹ provides strong earnings visibility. The P/E ratio of 29.2 is slightly below the industry average of 30.9, suggesting fair valuation. Dividend yield of 0.83% adds modest income support. However, the PEG ratio of 2.10 indicates the stock is priced above its growth potential, and quarterly PAT declined (654 Cr vs 724 Cr), showing short-term earnings pressure.
💰 Entry Price Zone: Ideal accumulation range is 5,200 ₹ – 5,350 ₹, near the DMA 50 (5,450 ₹) and DMA 200 (5,444 ₹), offering a safer entry below current levels.
📈 Exit Strategy / Holding Period: For existing holders, maintain a long-term horizon (3–5 years) given strong ROE/ROCE and low debt. Consider partial profit booking near 5,900 ₹ – 6,000 ₹ resistance levels. Dividend yield provides modest income, while long-term compounding potential remains strong.
✅ Positive
- Strong ROCE (19.5%) and ROE (19.9%) reflect efficiency and profitability.
- Debt-to-equity ratio of 0.06 ensures financial stability.
- EPS of 196 ₹ supports earnings visibility.
- FII holdings increased (+0.18%), signaling foreign investor confidence.
⚠️ Limitation
- PEG ratio of 2.10 suggests overvaluation relative to growth.
- Quarterly PAT declined (-3.35%), showing short-term earnings pressure.
- DII holdings decreased (-0.15%), showing reduced domestic support.
📉 Company Negative News
- No major negative news reported, but declining quarterly profits are a concern.
📈 Company Positive News
- Strong long-term profitability metrics (ROCE and ROE).
- Stable financial structure with negligible debt.
🏭 Industry
- Industry P/E at 30.9 suggests moderate sector valuation.
- Pharmaceutical sector benefits from consistent demand and innovation-driven growth.
🔎 Conclusion
ALKEM is a fundamentally strong candidate for long-term investment, supported by high ROE/ROCE, strong EPS, and negligible debt. Entry near 5,200–5,350 ₹ provides better margin of safety. Hold for 3–5 years to benefit from compounding, but monitor quarterly earnings and valuation metrics. Partial exits near 5,900–6,000 ₹ resistance levels are advisable to lock in gains.